Bleocin Dosage/Direction for Use

Intravenous Injection: The usual adult dosage is 15-30 mg (potency) of bleomycin hydrochloride dissolved in a suitable injection solution of approximately 5-20 mL such as physiological saline solution or dextrose solution and administered slowly by the intravenous route. When severe fever is noted, Bleocin should be administered at 5 mg (potency) or lower per dose.
Intramuscular and Subcutaneous Injection: The usual adult dosage is 15-30 mg (potency) of bleomycin hydrochloride dissolved in suitable solution of approximately 5 mL such as physiological saline solution and administered intramuscularly or subcutaneously.
When Bleocin is administered subcutaneously around the affected area, the concentration of bleomycin hydrochloride should be 1 mg (potency)/1 mL or less.
Intraarterial Injection: The usual adult dosage is 5-15 mg (potency) of bleomycin hydrochloride dissolved in suitable injection solution such as physiological saline solution or dextrose solution and injected in a single dose or continuously.
Frequency of Injection: Bleocin is administered twice a week, as a rule. This dose frequency may be increased to once daily (every day) or decreased to once a week depending on symptoms.
Total Dose: The total administered dose of bleomycin hydrochloride should be 300 mg (potency) or less to achieve tumor clearance.
Precautions concerning Dosage and Administration: Even with a comparatively low dose of Bleocin, adverse reactions may occur because adverse reactions are highly variable among individuals. Careful attention should be paid to the Precautions.
When administered, Bleocin should be started at a low dose depending on the symptoms and conditions of the patient.
A total dose should not exceed 300 mg (potency). The fact should be kept in mind that administration via multiple routes may lead to increase in the total dose.
[Results at the time of reevaluation showed incidences of pulmonary manifestation such as interstitial pneumonia and pulmonary fibrosis were 6.5% for a total dose of ≤150 mg (potency), 10.2% for 151-300 mg (potency), and 18.8% for ≥301 mg (potency), indicating increased incidences along with increases in total dose.]
The total dose of bleomycin administered in patients receiving peplomycin should be expressed as the sum of the administered amount of peplomycin and bleomycin, as a rule.